Literature DB >> 19175366

Antigenotoxic, antioxidant and lymphocyte induction effects produced by pteropodine.

Rogelio Paniagua-Pérez1, Eduardo Madrigal-Bujaidar, Dolores Molina-Jasso, Susana Reyes-Cadena, Isela Alvarez-González, Laura Sánchez-Chapul, Javier Pérez-Gallaga.   

Abstract

Pteropodine is a heterohimbine-type oxindole alkaloid specifically isolated from 'Cat's claw' (Uncaria tomentosa), a plant that has shown cytostatic, anti-inflammatory and antimutagenic properties and is used in traditional medicine to cure a number of diseases. In this report, we studied the ability of pteropodine to decrease the rate of sister-chromatid exchanges and micronucleated polychromatic erythrocytes in mice administered doxorubicin. We also determined its capacity to induce lymphocyte production in mice as well as its free radical scavenging potential by applying the DPPH assay. We found pteropodine (100-600 mg/kg) to significantly decrease the frequency of sister-chromatid exchanges and micronucleated polychromatic erythrocytes in mice administered with 10 mg/kg of doxorubicin. Furthermore, we determined that pteropodine partially corrected bone marrow cytotoxicity induced by doxorubicin, as it showed an improvement in the rate of polychromatic erythrocytes. Besides, 600 mg/kg of pteropodine increased 25.8% of the production of lymphocytes over the control value along a 96-hr assay, and it exhibited a strong capacity to trap the DPPH-free radical (98.26% with 250 microg/ml). Our results establish that pteropodine is an effective antimutagen in the model used, and suggest that pteropodine deserves further research in the area of cell protective potential and its mechanism of action.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19175366     DOI: 10.1111/j.1742-7843.2008.00366.x

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  6 in total

Review 1.  Spirocyclic derivatives as antioxidants: a review.

Authors:  Karen Acosta-Quiroga; Cristian Rojas-Peña; Luz Stella Nerio; Margarita Gutiérrez; Efraín Polo-Cuadrado
Journal:  RSC Adv       Date:  2021-06-21       Impact factor: 4.036

2.  Synthesis of novel spirooxindolo-pyrrolidines, pyrrolizidines, and pyrrolothiazoles via a regioselective three-component [3+2] cycloaddition and their preliminary antimicrobial evaluation.

Authors:  Guansheng Wu; Liang Ouyang; Jie Liu; Shi Zeng; Wei Huang; Bo Han; Fengbo Wu; Gu He; Mingli Xiang
Journal:  Mol Divers       Date:  2013-03-07       Impact factor: 2.943

3.  Uncaria tomentosa for Reducing Side Effects Caused by Chemotherapy in CRC Patients: Clinical Trial.

Authors:  I L G Farias; M C S Araújo; J G Farias; L V Rossato; L I Elsenbach; S L Dalmora; N M P Flores; M Durigon; I B M Cruz; V M Morsch; M R C Schetinger
Journal:  Evid Based Complement Alternat Med       Date:  2011-08-21       Impact factor: 2.629

4.  Treatment with Uncaria tomentosa Promotes Apoptosis in B16-BL6 Mouse Melanoma Cells and Inhibits the Growth of B16-BL6 Tumours.

Authors:  Ali Zari; Hajer Alfarteesh; Carly Buckner; Robert Lafrenie
Journal:  Molecules       Date:  2021-02-18       Impact factor: 4.411

5.  Uncaria tomentosa exerts extensive anti-neoplastic effects against the Walker-256 tumour by modulating oxidative stress and not by alkaloid activity.

Authors:  Arturo Alejandro Dreifuss; Amanda Leite Bastos-Pereira; Isabella Aviles Fabossi; Francislaine Aparecida Dos Reis Lívero; Aline Maria Stolf; Carlos Eduardo Alves de Souza; Liana de Oliveira Gomes; Rodrigo Polimeni Constantin; Aline Emmer Ferreira Furman; Regiane Lauriano Batista Strapasson; Simone Teixeira; Aleksander Roberto Zampronio; Marcelo Nicolás Muscará; Maria Elida Alves Stefanello; Alexandra Acco
Journal:  PLoS One       Date:  2013-02-07       Impact factor: 3.240

Review 6.  Medicinal Plants from Mexico, Central America, and the Caribbean Used as Immunostimulants.

Authors:  Angel Josabad Alonso-Castro; María Del Carmen Juárez-Vázquez; Nimsi Campos-Xolalpa
Journal:  Evid Based Complement Alternat Med       Date:  2016-03-03       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.